Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOSAICO HIV Vaccine Study
NCT03964415Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2019
- Primary completion
- Aug 2023
- Modality
- Prophylactic Vaccines, Recombinant Proteins and Enzymes, DNA Vaccines
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of Ad26.Mos4.HIV, clade C gp140 and mosaic gp140 in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants With Confirmed Human Immunodeficiency Virus (HIV)-1 Infections Diagnosed Between the Month 7 and Month 24 Visits (Per-protocol [PP] Set) and Number of Participants With a Confirmed Human Immunodeficiency Virus (HIV)-1 Infections Diagnosed Between the Month 7 and Month 30 Visits (PP Set). Started Oct 2019; status: completed.
02
Drugs
Ad26.Mos4.HIVclade C gp140mosaic gp140
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03964415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03964415.